A Houston entrepreneur is creating a fun and educational platform for children that helps to preserve their heritage. Photo by Kelly Sikkema/Unsplash

Theoharis Dimarhos grew up in a family determined to follow tradition. As a child, his mother serenaded him with old Greek folk songs he still remembers, and his parents made speaking Greek a rule of the house. Dimarhos lived the immigrant family experience, and now he's developed a modern way to preserve pass down culture to the masses.

"My parents came from Greece in 1981, and in typical fashion, they didn't have much and didn't speak the language at all," says Dimarhos, who was born in Cleveland, Ohio. Living the first-generation American experience, he watched his parents work tirelessly to provide for the family and maintain their Greek culture in America.

Dimarhos did get his own immigrant story when his parents decided to move back to Greece when he was 7. After assimilating to Greece, he traveled back to the United States for college, where he learned to readjust once more.

"I kind of got that immigrant experience a couple of times," he says.

While Dimarhos grew up surrounded by his own heritage, he began to realize that "our native cultures were destined to fade if there wasn't a more modern way for children and our little siblings to learn more about their roots."

When talking with his friends from other countries outside of Greece, a general consensus grew: without modern learning, family heritage would slip away.

Enter: Ellis, an app that helps children connect to their culture. The app includes Greek songs, fables, mythology, history, and language.

Named after Ellis Island, a gateway into the United States for so many immigrants in history, Ellis nurtures Greek tradition in a way that caters to children through technology.

"I've always seen [Ellis Island] as a monument of courage to chase your dreams. . .people came and built this country, but also never forgot where they came from."

Interactive technology is becoming a large part of early childhood education, especially during COVID-19, as more families are at-home with children learning virtually. Children are the targets of over 80 percent of the top-selling paid apps in the education category of the iTunes store, according to a published analysis by Carly Shuler in 2012.

Dimarhos and his wife are deeply tied to their Greek heritage, and hope to pass that history and appreciation to their own children once they start a family.

"We wanted to make sure that there was a 21st century way for us and for our children to learn that goes beyond books," he says. "Something that's a little more immersive and fun — fun is very important — and educational."

Ellis is currently being beta tested with a group of 200 active users within the Greek community. The app, which targets ages 0-8, rolls out weekly content to parents.

"I'm receiving texts from friends who are parents begging me to put more content out because they need something to keep their children occupied," says Dimarhos. "Not only are regular schools closed, but cultural schools that are offered by the community are also closed and struggling to open back up."

Time spent on the app can be as short as five minutes and stretch into hours of learning time.

"The goal is always for children to pick up little phrases and words each time they listen," explains Dimarhos.

The stories and songs are all audio-based, tying into activities like waking up, eating breakfast, and bathtime.

"There's something magical about tying in an audio story or song with everyday tasks for kids," says Dimarhos.

Dimarhos parents see the app as "the next step of passing down the torch of our culture," he says.

"They tried to do it with the tools that they had for myself and my sister. . .We're trying to do the exact same thing that they did and their parents did, just with the tools that technology offers us," he says.

Dimarhos, who previously worked in economic development in Austin, had his first experience with startups when his former boss gave him a chance to work with his international accelerator for startups.

"I got my opening into the tech world through the international accelerator and seeing amazing immigrant founders create jobs and strive to do great things in America," he shares.

"Quite honestly, a startup that celebrates different cultures couldn't have a better home than in Houston," he says, noting the massive immigrant population and variety of cultures in the city.

In Dimarhos' own life, he's come across immigrants as well as first and second generation Americans who wish to preserve their own cultures.

"They've wished there was a more modern way to have access to those resources," he explains.

In the future, Dimarhos intends to quickly broaden the app to "launch in every immigrant community in the United States and around the world."

Connecting to cultural roots is something Dimarhos feels is "sacred" to immigrant families.

"It's something that you have the obligation from your parents as they give you everything for you to succeed in life. You kind of carry that obligation to carry that torch and pass it on to your children and their children," he explains.

"We grow up with that and the vision and the mission is just to create something that makes that a little bit easier to keep our cultures alive. I honestly think it's part of what makes this country great," he says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech startup secures $10M seed round to propel cancer-fighting therapy from bench to bedside

fresh funding

A Houston biotech company based off research out of UTHealth Houston has raised seed funding to continue developing its cancer-fighting therapeutic.

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and Crescent Enterprises' VC arm, CE-Ventures. The round also included participation from Portal Innovations, Alexandria Venture Investments, Linden Lake Labs, and several pre-seed investors.

“We are thrilled to have the support of such experienced investors who share our vision of bringing transformative cancer therapies to patients in need,” Michael Torres, CEO of CrossBridge Bio, says in a news release. Torres served as an entrepreneur in residence of ACT.

The company is working on the next-generation of antibody-drug conjugates (ADC) therapeutics that process dual payloads as targeted treatments for a set of challenging cancers. The innovative treatment is based on research from UTHealth experts Dr. Kyoji Tsuchikama and Dr. Zhiqiang An.

“Our dual-payload ADC technology is designed to deliver synergistic therapeutic effects using highly stable linkers that ensure payload release only within the targeted cancer cells, thereby maximizing their therapeutic effectiveness while minimizing the liabilities associated with uptake in unintended tissues, as seen with many of today’s cancer treatments," Torres continues.

He explains that the funding will toward advancing CrossBridge's first development candidate, CBB-120, into preclinical non-GLP toxicology studies in addition to derisking the company’s proprietary linker technology with dual-payload applications, per the release.

As a result of the raise, William McKeon, president and CEO of the Texas Medical Center, and Damir Illich, manager of life sciences of CE-Ventures, will join CrossBridge Bio’s board of directors.

“We are proud to back CrossBridge Bio in their mission to develop the next generation of cancer therapies,” McKeon says in the release. “Their dual-payload ADCs are designed to deliver targeted drug release within cancer cells with greater stability, precision, and control. These breakthrough advancements have the potential to change patients’ lives worldwide and we look forward to helping drive their development.”

Houston firm scores 2 grants to support testing treatment for addiction, neurodegenerative diseases

money moves

A Houston organization devoted to developing early-stage therapeutic and medical device technologies announced fresh funding for one of its startups.

Fannin Partners' Goldenrod Therapeutics, received a $320,000 Phase I SBIR grant from the National Institute on Drug Abuse (NIDA) for studies regarding both addiction medicine and neurodegenerative diseases with a single lead candidate, called 11h.

The grant will fund studies in rodent models of methamphetamine addiction and the efficacy of 11h for the tiny patients. This is the next step in charting the established promise of 11h in substance use disorders using animal models. Existing therapies for opioid and alcohol addiction have high relapse rates, and there are currently no FDA-approved medications for Stimulant Use Disorders (StUDs).

Previous preclinical studies demonstrated that 11h was effective in the fight against cocaine addiction. The goal is to note similar results in methamphetamine addiction.

At the same time, Fannin was also granted a $250,000 Early Hypothesis Development Award from the Department of Defense (DoD) to study 11h in neurodegenerative diseases. Specifically, the funds will be used to work on rodent models of multiple sclerosis (MS).

Fannin’s goal is to develop an oral medication that slows or reverses the progression of MS, while also improving the patient’s quality of life by relieving symptoms. Many MS medications come with the threat of liver injury and increased risk of infection, so sidestepping those is also a hope for 11h.

In fact, 11h was developed to minimize the toxicities associated with existing PDE4 inhibitors. Early evidence shows that the drug is not only effective, but also safe and easily tolerable.

“NIDA’s continued support of our SUD program highlights the potential of 11h to significantly improve the standard of care for patients suffering from these conditions, some of which lack any approved pharmaceutical options," says Dr. Atul Varadhachary, managing partner at Fannin, in a news release. “The additional DoD funding will allow us to explore 11h’s impact on neurodegenerative disease, as well. We are grateful for the support from both organizations as we advance 11h towards clinical development.”

Previous steps in 11h’s development were funded by a $350,000 Phase I SBIR grant from NIDA. 11h is part of NIDA’s Addiction Treatment Discovery Program. Next year, Fannin will likely scale up Good Manufacturing Practices (GMP) production and complete toxicology studies. This will lead to clinical trials for 11h for cocaine use disorder and other StUDs. But don’t expect Fannin to be quiet for long. Its next big discovery is always on the horizon.

Autonomous truck company taps breaks on Houston-Dallas route

re-routing

Autonomous truck company Aurora Innovation says it won't start hauling freight without humans on board until April of next year, a delay from previous statements that commercial service would begin by the end of 2024.

The Pittsburgh company on Wednesday said the April launch of driverless semis traveling from Dallas to Houston — originally announced last year — will be “modestly later” than the company had intended. The company also previously announced a partnership with Uber.

The company told investors on its third-quarter earnings conference call that it has made progress toward ensuring its trucks will operate safely.

Remaining obstacles are “primarily in the areas of some elements of surface street driving and some elements of construction that we see on the freeway,” CEO Chris Urmson said. “We want to have extremely high confidence in the system as we as we go forward.”

The company will start with about 10 autonomous tractor-trailers and move to “tens” of trucks by the end of next year, Urmson said.

“This shift to our timeline will have a negligible financial impact and does not affect our scaling efforts on our path to self-funding," Urmson said.

Aurora also intends to haul freight without human drivers from Fort Worth, Texas, to Phoenix later in 2025, Urmson said.

Aurora in August added nearly $500 million to its balance sheet with a capital raise in August, which the company expects to fund the initial phases of its strategy to scale up driverless trucking.